1. Home
  2. Analysis
  3. Keppra
  4. Procysbi

Keppra and Procysbi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keppra (levetiracetam) and Procysbi (cysteamine bitartrate). Common drug interactions include blood potassium increased among females and eye irritation among males.

The phase IV clinical study analyzes what interactions people have when they take Keppra and Procysbi. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Procysbi?

Procysbi has active ingredients of cysteamine bitartrate. eHealthMe is studying from 998 Procysbi users. Check the latest studies of Procysbi.

On Jul, 12, 2026

13 people who take Keppra and Procysbi together, and have interactions are studied.

Keppra and Procysbi drug interactions.

What are the common drug interactions of Keppra and Procysbi, by gender? *:

female:

  1. Blood potassium increased
  2. Blood calcium decreased

male:

  1. Eye irritation
  2. Abdominal distension
  3. Blood pressure diastolic increased
  4. Death
  5. Feeding disorder (when children refuse to eat certain food groups)
  6. Nausea (feeling of having an urge to vomit)
  7. Pyrexia (fever)
  8. Viral infection
  9. Vomiting

What are the common drug interactions of Keppra and Procysbi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Blood calcium decreased
  2. Blood potassium increased
  3. Blood pressure diastolic increased
  4. Death
  5. Nausea (feeling of having an urge to vomit)
  6. Pyrexia (fever)
  7. Viral infection
  8. Vomiting

30-39:

  1. Blood calcium decreased
  2. Blood potassium increased

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Cystinosis (abnormal accumulation of the amino acid cystine): 9 people, 69.23%
  2. Corneal Deposits: 3 people, 23.08%
  3. Amino Acid Metabolism Disorder: 3 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and Procysbi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Keppra and Procysbi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Procysbi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Keppra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Procysbi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam and cysteamine bitartrate (the active ingredients of Keppra and Procysbi, respectively), and Keppra and Procysbi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.